Century Therapeutics Inc - Asset Resilience Ratio
Century Therapeutics Inc (IPSC) has an Asset Resilience Ratio of 24.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Century Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Century Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Century Therapeutics Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Century Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore IPSC long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $70.07 Million | 24.41% |
| Total Liquid Assets | $70.07 Million | 24.41% |
Asset Resilience Insights
- Good Liquidity Position: Century Therapeutics Inc maintains a healthy 24.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Century Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Century Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Century Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Century Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.70% | $55.26 Million | $223.70 Million | -12.34pp |
| 2024-12-31 | 37.05% | $130.85 Million | $353.22 Million | +2.28pp |
| 2023-12-31 | 34.77% | $125.41 Million | $360.69 Million | -12.76pp |
| 2022-12-31 | 47.53% | $231.23 Million | $486.54 Million | +9.47pp |
| 2021-12-31 | 38.05% | $166.43 Million | $437.38 Million | -7.41pp |
| 2020-12-31 | 45.46% | $48.54 Million | $106.78 Million | +4.23pp |
| 2019-12-31 | 41.23% | $37.48 Million | $90.90 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more